The relevance of pharmacokinetics in the development of biotechnology products

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 21, Issue 2, 1996, Pages 93-103

  Toon, S ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Binding proteins; Bioanalysis; Biotechnology; Drug development; Pharmacokinetics

Indexed keywords

CALCITONIN; DRUG ANTIBODY; DRUG BINDING PROTEIN; ERYTHROPOIETIN; FOLLITROPIN; GROWTH HORMONE; HUMAN GROWTH HORMONE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT HUMAN INSULIN; RECOMBINANT INTERLEUKIN 2;

BIOASSAY; BIOTECHNOLOGY; CONFERENCE PAPER; DRUG ANALYSIS; DRUG CONCENTRATION; DRUG DEVELOPMENT; DRUG RELEASE; FEMALE; FOLLITROPIN BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; LYMPHATIC SYSTEM; NORMAL HUMAN; PHARMACOKINETICS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030017103     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190257     Document Type: Conference Paper

References (71)

1. Biotech '96. Pursuing Sustainability. (1995) : Palo Alto, Ernst and Young LCP.
2. Dollery C.T. (1973) : Pharmacokinetics - master or servant? Eur, J. Clin. Pharmacol., 6, 1-2.
3. Riegelman S., Rowland M., Benet L.Z. (1973) : Use of isotopes in bioavailability testing. J. Pharmacokinet. Biopharm., 1, 83-87.
4. Ariëns E.J. (1984) : Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol., 26, 663-668.
5. Bailey G.S. (1984) : Radioiodination of proteins. Methods Mol. Biol , 1, 325.
6. Parker C.W. (1990) : Radiolabelling of proteins. Methods Enzymol., 182, 721-737.
7. Woltanski K-P., Besch W., Keilacker H., Ziegler, M., Kohnert K-D. (1990) : Radioiodination of peptide hormone and immunoglobulin preparations: comparison of the chloramine T and lodogen method. Exp. Clin. Endocrinol., 95, 39-46.
8. Cossum P.A., Dwyer K.A., Roth M., et al. (1992) : The disposition of a human relaxin (hRIx-2) in pregnant and non-pregnant rats. Pharm. Res., 9, 415-420.
9. Bennett H.P.J., McMartin C. (1979) : Peptide hormones and their analogues: distribution, clearance, from the circulation and inactivation in vivo. Pharmacol. Rev., 30, 247-292.
10. Cameron D.P., Burger H.G., Catt K. J., Dong A. (1969) : Metabolic clearance rate of radioiodinated human growth hormone in man. J. Clin. Invest., 48, 1600-1608.
11. Parker M.L., Utinger R.D., Daughaday W.H. (1962) : Studies on human growth hormone. II. The physiological disposition and metabolic fate of human growth hormone in man. J. Clin. Invest., 41, 262-268.
12. Regoeczi E. (1987) : Iodine-labelled plasma proteins. Boca Raton, CRC, pp.6, 112, 116-117.
13. Schwenk W.F., Tsalikain E., Beaufrere B., Haymond M.W. (1985) : Recycling of an amino acid label with prolonged isotope infusion: implications for kinetic studies Am. J. Physiol., 248, E482-E487.
14. Bloom H.G., Crocket D.J., Stewart F.S. (1958) : The effects of radiation on the stability of radioiodinated human serum albumin. Br. J. Radiol., 31, 377-384.
15. Van der Abbeele A.D., Aronson R.A., Adelstein S.J., Kassis A.I. (1988) : Does the in vitro immunoreactivity of an antibody reflect its in vivo behaviour? J. Nucl. Med. Allied Sci., 32, 260-267.
16. Chan D.W., Perlstein M.T. (1987) : Immunoassay - A Practical Guide. New York, Academic Press.
17. Kemeny D.M., Challacombe S.J., (eds) (1988) : ELISA and other Solid Phase Immunoassays. New York, Wiley.
18. Gosling J.P. (1990) : A decade of development of immunoassay methodology. Clin. Chem., 36, 1408-1427.
19. Chen A.B., Baker D.L., Ferraiolo B.L. (1991) : Points to consider in correlating bioassays and immunoassays in the quantitation of peptides and proteins. In: Garzone P.D., Colburn W.A., Mokotoff W.A. (Eds) Peptides, Peptoids and Proteins. Cincinnati, Harvey Whitney Books, pp. 53-71.
20. La Bella F.S., Geiger J.D., Glavin G.B. (1985) : Administered peptides inhibit the degradation of endogenous peptides the dilemma of distinguishing direct from indirect effects. Peptides, 6, 645-660.
21. Pringle P.J., Hindmarsh P.C., De Silvio L., Teale J.D., Kurtz A.B., Brook C.G.D. (1989) : The measurement and effect of growth hormone in the presence of growth hormone-binding antibodies. J. Endocrinol., 121, 193-199.
22. Lucas C., Bald L.N., Martin M.C., et al. (1989) : An enzyme linked immunosorbent assay to study human relaxin in human pregnancy and in pregnant rhesus monkeys. J. Endocrinol., 120, 449-457.
23. Porchet H.C., Le Cotonnec J-Y., Loumaye E. (1994) : Clinical pharmacology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modelling after repeated subcutaneous administration. Fertil. Steril., 61, 687-695.
24. Le Cotonnec J-Y., Porchet H.C., Beltrami V., Khan A.Z., Toon S., Rowland M. (1994) : Clinical pharmacology of recombinant human follicle stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertil. Steril., 61, 669-678.
25. Khan A.Z , Davis J.D., Toon, S., et al. (1994) : A study investigating the pharmacokinetic and pharmacodynamic equivalence of two r-hGH formulations administered subcutaneously. Br. J. Clin. Pharmacol., 38, 177P.
26. Toon S. (1995) : Problems of assessment of bioavailability/bioequivalence of administered endogenous substances. In: Blume H.H., Midha K.K., (Eds) Bio-International 2. Bioavailability, Bioequivalence and Pharmacokinetic Studies. Stuttgart, Medpharm, pp. 161-170.
27. Mordenti J., Chappell W. (1989) : The use of interspecies scaling in toxicokinetics. In: Yacobi A., Skelly J.P., Batra V.K. (Eds) Toxicokinetics and New Drag Development. New York, Pergamon, pp. 42-96.
28. Mordenti J., Green J.D. (1991) : The role of pharmacokinetics and pharmacodynamics in the development of therapeutic proteins. In: Rescigno A., Thakur A.K., (Eds) New Trends in Pharmacokinetics. New York, Plenum, pp. 411-424.
29. Mordenti J., Chen S., Moore J., Ferraiolo B. (1990) : Total body clearance of recombinant and synthetic proteins are well described by an allometric relationship. Toxicologist, 10, 239.
30. Mordenti J., Shaieb D., Chow P., et al. (1991) : Pre-clinical safety evaluation strategy for biomacromolecules - a perspective. In: Gad S.C. (Ee.d) Safety Assessment for Pharmaceuticals. New York, Van Nostrand Reinhold.
31. Working P.K. (1992) : Potential effects of antibody induction by protein drags. In: Ferraiolo B.L., Mohler M.A., Gloff C.A. (Eds). Protein Pharmacokinetics and Metabolism. New York, Plenum Press, pp. 73-92.
32. Vallbracht A., Trainer J., Flehmig B., Joester K.E., Niethammer D. (1981) : Interferon neutralising antibodies in a patient treated with human fibroblast interferon. Nature, 289, 496-497.
33. Trown P.W., Kramer M.J., Dennin R.A., et al. (1983) : Antibodies to human leukocyte interferon in cancer patients. Lancet, 1, 81-84.
34. Spiegel R.J., Spicehandler J R , Jacobs S.L., Oden E.M. (1986) : Low incidence of neutralising factors in patients receiving recombinant-alpha-2b interferon (lntron-A) Am. J. Med., 80, 223-228.
35. Hawkins M., Horning S., Konrand M., et al. (1985) : Phase I evaluation of a synthetic mutant of β-interferon. Cancer Res., 45, 5914-5920.
36. Kaplan S.L., August G.P , Blethen S.L., et al. (1986) : Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. Lancet, 1, 697-700.
37. Fineberg S., Galloway J., Fineberg N., Rathburn M., Hufferd S. (1983) : Immunogenicity of recombinant DNA human insulin. Diabetologia, 25, 465-469.
38. Nilsson I.M., Beratorp E., Zettervall O., Dahlback B. (1990) : Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in haemophilia A patients. Blood, 75, 378-383.
39. Queseda J.R., Gutterman J.U. (1983) : Clinical study of rccombinant DNA-produced leukocyte interferon (clone A) in an intermittent schedule in cancer patients. J. Natl. Cancer Inst., 70, 1041-1046.
40. Rosenblum M.G., Unger B.W., Gutterman J.U., Hersh E.M., David G.S., Fincke J.M. (1985) : Modification of human leucocyte interferon pharmacology with monoclonal antibody. Cancer Res., 45, 2421-2424.
41. Capon D.J , Charnow S.M., Mordenti J., et al. (1989) : Designing CD4 immunadhesins for AIDS therapy. Nature, 337, 525-531.
42. Sell S. (1987) : Immunology. Immunopathology and Immunity, 4th edn. Amsterdam, Elsevier.
43. Berson S.A., Yalow R.S. (1966) : State of human growth hormone in plasma and changes in stored solutions of pituitary growth hormone. J. Biol. Chem., 241, 5745-5749.
44. Baumann G., Stolar M.W., Amburn K., Barsario C.P., DeVries B.C. (1986) : A specific growth hormone-binding protein in human plasma: initial characterization. J. Clin. Endocrinol. Metab., 62, 134-141.
45. Baumann G., Shaw M A (1990) : A second lower affinity growth hormone binding protein in human plasma. J. Clin. Endocrinol. Metab., 70, 680-686.
46. Baumann G., Amburn K., Shaw M.A. (1988) : The circulating growth hormone (GH)-binding protein complex: A major constituent of plasma GH in man. Endocrinology, 122, 976-984.
47. Baumann G., Shaw M.A., Amburn K. (1989) : Regulation of plasma growth hormone-binding proteins in health and disease. Metabolism, 38, 683-689.
48. Baumann G., Amburn K., Buchanan T.A. (1987) : The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone. J. Clin. Endocrinol. Metab., 64, 657-660.
49. Baumann G., Shaw M.A., Buchanan T.A. (1988): In vivo kinetics of a covalent growth hormone-binding protein complex. Metabolism, 38, 330-333.
50. Leung D.W., Spencer S.A., Cachianes G. (1987) : Growth hormone receptor and serum binding protein: purification cloning and expression. Nature, 330, 537-543.
51. Amit T., Barkey R.J., Youdim M.B.H., Hochberg Z. (1990) : A new and convenient assay for growth hormone-binding protein activity in human serum. J. Clin. Endocrinol. Metab., 71, 474-479.
52. Laron Z., Klinger B., Erster B., Silbergeld. (1989) : Serum GH binding protein activities identifies the heterozygous carriers for Laron type dwarfism. Acta Endocrinol., 121, 603-608.
53. Baumann G., Shaw M.A., Merimee T.J. (1989) : Low levels of high-affinity growth hormone-binding protein in African pygmies. N. Engl. J. Med., 320, 1705-1709.
54. Rutanen E.M., Pekonen F. (1990) : Insulin-like growth factors and their binding proteins. Acta Endocrinol., 123, 7-13.
55. Zapf J., Hauri C., Waldvogel M., et al. (1989) : Recombinant insulin-like growth factor-I induces its own specific carrier protein in hypophysectomized and diabetic rats. Proc. Natl. Acad. Sci. USA, 86, 3813-3817.
56. Binoux M., Lalou C., Lassarre C., Segovia B. (1994) Regulation of IGF bioavailability by IGFBP proteases. In: Baxter R.C., Gluckman P.D., Rosenfeld R.G. (Eds). The Insulin-like Growth Factors and their Regulatory Proteins. Amsterdam, Elsevier, pp. 217-226.
57. Havredaki M., Barona F. (1985) : Variations in Interferon inactivators and/or inhibitors in human serum and their relationship to interferon therapy. Jpn. J. Med. Sci. Biol., 38, 107-111.
58. Fernandez-Botran R., Vitetta E.S. (1990) : A soluble, high-affinity, interleukin-4-binding protein is present in the biological fluids of mice. Proc. Natl. Acad. Sci. USA, 87, 4202-4206.
59. Lelchuk R., Playfair J.H.L. (1985) : Serum IL-2 inhibitor in mice. I. Increase during infection. Immunology, 56, 113-118.
60. Malik S., Lantz M. Slevin M., Olsson I. (1991) : Infusion of recombinant human tumour necrosis factor (rhTNF) causes an increase in circulating TNF-binding protein in man. Int. J. Exp. Pathol., 72, A6.
61. Kleinbloesem C.H., van Brummelen P., van de Linde J.A., Voogol P.J., Breimer D.D. (1984) : Nifedipine: kinetics and dynamics in healthy subjects. Clin. Pharm. Ther., 35, 742-749.
62. Van Cauter E., Refetoff S. (1985) : Multifactorial control of the 24-hour secretory profiles of pituitary hormones. J. Endocrinol. Invest., 8, 381-391.
63. Hulse J.A., Rosenthal S.M., Cuttler L., Kaplan S.L., Grumbach M.M. (1986) : The effect of pulsatile administration, continuous infusion and diurnal variation on the growth hormone response to GH-releasing hormone in normal men. J. Clin. Endocrinol. Metab., 63, 872-878.
64. Clark R.G., Jansson J-O., Isaksson O., Robinson I.C.A.F. (1985) : Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats. J. Endocrinol., 104, 53-61.
65. Tuvemo T. (1989) : What is the best mode of growth hormone administration? Acta Paediatr. Scand., 362 Suppl., 44-49.
66. Tam C.S., Heersche J.N.M., Murray T.M., Parsons J.A. (1982) : Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology, 110, 506-512.
67. Klabunde R.E., Burke S.E., Henkin J. (1990) : Enhanced lytic efficacy of multiple bolus injections of tissue plasminogen activator in dogs. Thromb. Res., 58, 511-517.
68. Vickery B.H. (1991) : Biological actions of synthetic analogues of luteinizing hormone-releasing hormone. In: Garzone P.D., Colburn W.A., Mokotoff M. (Eds) Pharmacokinetics and Pharmacodynamics. Vol. 3. Peptides, Peptoids and Proteins. Cincinnati, Harvey Whitney Books, pp. 41-49.
69. Wills R.J., Dennis S., Spiegel H.E., Gibson D.M., Nadler P.I. (1984) : Interferon kinetics and adverse reactions after intravenous, intramuscular and subcutaneous injection. Clin. Pharm. Ther., 35, 722-727.
70. Supersaxo A., Hein W., Gallati H., Steffen H. (1988) : Recombinant human Interferon alpha-2a: delivery to lymphoid tissue by selected modes of application. Pharm. Res., 5, 472-476.
71. Supersaxo A., Hein W.R., Steffen H. (1990) : Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res., 7, 167-169.